Literature DB >> 20473700

Superinfection during treatment of nosocomial infections with tigecycline.

E García-Cabrera1, M E Jiménez-Mejías, M V Gil Navarro, M J Gómez-Gómez, C Ortiz-Leyba, E Cordero, J Pachón.   

Abstract

We performed a retrospective and observational study of 51 patients treated with tigecycline, as the treatment for nosocomial infections due to multidrug-resistant microorganisms, to evaluate the superinfection rate and their etiologies. Superinfections were diagnosed in 12 (23.5%) patients (seven due to Pseudomonas aeruginosa, 13.7%) and one patient had P. aeruginosa colonization. Five patients with superinfection died (41.6%), three due to superinfections and two to underlying diseases. The superinfection rate observed during tigecycline treatment is higher than that previously reported. Pseudomonas aeruginosa is the most frequent agent, being the cause of 58.5% of all superinfections.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473700     DOI: 10.1007/s10096-010-0942-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  15 in total

Review 1.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2005-02-15       Impact factor: 21.405

3.  In vitro activity of tigecycline, a new glycylcycline, tested against 1,326 clinical bacterial strains isolated from Latin America.

Authors:  Ana C Gales; Ronald N Jones; Soraya S Andrade; Andrea S Pereira; Hélio S Sader
Journal:  Braz J Infect Dis       Date:  2006-01-06       Impact factor: 1.949

4.  Correction of a reference to clinical laboratory standards institute interpretive criteria.

Authors:  Matthew A Wikler; Mary Jane Ferraro
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

5.  Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam.

Authors:  Johannes Breedt; Jüri Teras; Janis Gardovskis; Frans Jacobus Maritz; Tiit Vaasna; Douglas Patrick Ross; Martine Gioud-Paquet; Nathalie Dartois; Evelyn J Ellis-Grosse; Evan Loh
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: Results from a phase 3, randomized, double-blind trial.

Authors:  Sarvajna Sacchidanand; Robert L Penn; John M Embil; Maria E Campos; Daniel Curcio; Evelyn Ellis-Grosse; Evan Loh; Gilbert Rose
Journal:  Int J Infect Dis       Date:  2005-09       Impact factor: 3.623

7.  Effect of tigecycline on normal oropharyngeal and intestinal microflora.

Authors:  Carl Erik Nord; Eva Sillerström; Elisabeth Wahlund
Journal:  Antimicrob Agents Chemother       Date:  2006-10       Impact factor: 5.191

8.  Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae.

Authors:  Michael W Daly; David J Riddle; Nathan A Ledeboer; W Michael Dunne; David J Ritchie
Journal:  Pharmacotherapy       Date:  2007-07       Impact factor: 4.705

9.  Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

Authors:  Takahiro Hirata; Asami Saito; Kunihiko Nishino; Norihisa Tamura; Akihito Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

10.  Endemic carbapenem-resistant Pseudomonas aeruginosa with acquired metallo-beta-lactamase determinants in European hospital.

Authors:  Cristina Lagatolla; Enrico A Tonin; Carlo Monti-Bragadin; Lucilla Dolzani; Francesca Gombac; Claudia Bearzi; Elisabetta Edalucci; Fabrizia Gionechetti; Gian Maria Rossolini
Journal:  Emerg Infect Dis       Date:  2004-03       Impact factor: 6.883

View more
  5 in total

1.  Case-control study of the risk factors for acquisition of Pseudomonas and Proteus species during tigecycline therapy.

Authors:  Ga Eun Park; Cheol-In Kang; Yu Mi Wi; Jae-Hoon Ko; Woo Joo Lee; Ji Yong Lee; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

2.  Excess deaths associated with tigecycline after approval based on noninferiority trials.

Authors:  Paritosh Prasad; Junfeng Sun; Robert L Danner; Charles Natanson
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

3.  Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy.

Authors:  R Guner; I Hasanoglu; S Keske; A K Kalem; M A Tasyaran
Journal:  Infection       Date:  2011-07-26       Impact factor: 3.553

4.  Mutational Evolution of Pseudomonas aeruginosa Resistance to Ribosome-Targeting Antibiotics.

Authors:  Fernando Sanz-García; Sara Hernando-Amado; José L Martínez
Journal:  Front Genet       Date:  2018-10-18       Impact factor: 4.599

Review 5.  Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.

Authors:  Shio-Shin Jean; Yin-Chun Chang; Wei-Cheng Lin; Wen-Sen Lee; Po-Ren Hsueh; Chin-Wan Hsu
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.